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by auto-ﬂuorescent target and effector cells and by non-speciﬁc cell death. We combined and adjusted existing
cell viability assays to develop a method that allows for highly reproducible, accurate, single cell analysis by
high throughput FACS, inwhich non-speciﬁc cell death is corrected for. In this assay the number of living, calcein
AM labeled cells that are green ﬂuorescent are quantiﬁed by adding a ﬁxed number of unlabeled calibration
beads to the analysis. Using this modiﬁed FACS calcein AM retention method, we found EC50 values to be highly
reproducible and considerably lower compared to EC50 values obtained by conventional assays, displaying the
high sensitivity of this assay.







The goal of anti-cancer therapy is to induce death of malignant cells.
Oncolytic agents induce cytotoxicity directly, or indirectly via antibody
dependent cell-mediated cytotoxicity (ADCC) or complement depen-
dent cytotoxicity (CDC). To determine the cytotoxicity of a compound
in vitro, a number of methods can be applied. The classic method is
the chromium 51 (51Cr) release assay,(Boyle, 1968; Thorn et al.,
1974) in which target cells are labeled with the radioactive compound
51Cr. After incubation with the compound of interest plus or minus ef-
fector cells or complement the amount of lysed target cells is deter-
mined by the amount of radioactivity in the supernatant. Because the
use of radioactive compounds requires skilled personnel, costly equip-
ment and laboratories, non-radioactive cytotoxicity assays have been
developed that rely on the release of naturally occurring intracellular
enzymes like lactate dehydrogenase (LDH) or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) from dying cells. The readout in
these assays is based on a chemical reaction related to the activity of
these enzymes. Both the LDH and the GAPDH assay do not discriminate
between cell death by the compound under study or non-speciﬁc cell
death, including that of effector cells, and results have to be compensat-
ed for that (Tajeddine et al., 2008; von Horsten et al., 2010). Anothergy F4-224, Academic Medical
ands.
erg).
. This is an open access article underalternative to the 51Cr release assay is the calcein release assay (Neri
et al., 2001; Galluzzi et al., 2009). In this assay, target cells are incubated
with calcein AM, a non-ﬂuorescent, hydrophobic and cell permeable
dye that easily enters living cells. In the cell cytoplasm, AM is cleaved
off by esterases via hydrolysis leaving calcein as a hydrophilic, green
ﬂuorescent dye that is released into the medium when the labeled
cells die. The read-out of this method is the green ﬂuorescence intensity
of the medium. Culture media and supplements like fetal bovine serum
(FBS) can be auto-ﬂuorescent, causing background signal that can reach
up to 40% of the signal observed at maximum cell death (Neri et al.,
2001). Other assays include the ATP luminescence assay and the lumi-
nescent ADCC Reporter Bioassay. The ATP luminescence assay relies
on the quantiﬁcation of intracellular ATP levels as a read-out for cell vi-
ability. As it does not discriminate between target and effector cells the
assay is not suitable for ADCC assays (Galluzzi et al., 2009; Bornstein
et al., 2009). In contrast, the ADCC reporter Bioassay (Promega) relies
on the activation of effector cells as a readout, and is therefore applied
exclusively for ADCC (Cheng et al., 2014).
We combined and adjusted existing cell viability assays to develop
an assay that allows for single cell analysis by high throughput FACS
and that corrects for non-speciﬁc cell death. In this assay the number
of living calcein AM labeled cells that are green ﬂuorescent are quanti-
ﬁed by adding a ﬁxed number of calibration beads. With this modiﬁed
FACS calcein AM retention assay we developed an improved, accurate,
high throughput ﬂow cytometer based method to determine cellular
cytotoxicity that can be applied in a variety of assays, including CDC
and ADCC of suspension and adherent cells.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Cell lines
The cell lines Raji, Ramos (Burkitt lymphoma) and SK-BR-3 (breast
cancer) (ATCC) were cultured according to the manufacturers' instruc-
tions. Raji and Ramos cells were grown in suspension at a cell density
of 4 × 105–2 × 106 or 2 × 105–1 × 106 cells/ml in RPMI 1640 (Life Tech-
nologies) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Gibco) and 1× penicillin/streptomycin (PS; Roche), hereafter
called complete medium for suspension cells. The adherent breast can-
cer cell line SK-BR-3 was cultured in McCoy's 5A medium (Sigma) sup-
plemented with 10% heat-inactivated FBS, 1× GlutaMAX™ 150 μl/ml
(Invitrogen), 1× PS hereafter referred to as complete medium for ad-
herent cells. Adherent cells were cultured to 80% conﬂuency, detached
with trypsin-EDTA (Invitrogen) and washed once before use.Fig. 1. Calcein AM labeling and analysis of live cells. (A) FACS acquisition of a ﬁxed number of 5
positive (gates C), dead cells are calcein-negative (gate D). This was conﬁrmed by DAPI stainin
easily separated from calcein-labeled target cells (gate C). (B) Equation to calculate the percent
cells in X’ is the amount of cells as depicted in Fig. 1, gates C. ‘Control’ is the average of at least a t
cells, but without test compound.2.2. Calcein labeling of suspension and adherent cells
Cells in suspension were washed and re-suspended in 10 nM
calcein AM (Becton Dickinson) diluted in RPMI 1640 supplemented
with 2% heat-inactivated fetal bovine serum at a cell concentration
of 1 × 106 cells/ml. Adherent cells were harvested three days prior
to the cytotoxicity assay and seeded at a density of 10,000 cells/
well in Poly-D-Lysine hydrobromide (Sigma) coated 96 well ﬂat bot-
tom culture plate (Corning® Costar® cell culture plates, Corning)
and cultured at 37 °C with 5% CO2. On the day of the cytotoxicity ex-
periment culture medium was replaced with McCoy's 5 A medium
(Sigma) supplemented with 2% heat-inactivated fetal bovine
serum, and 1× GlutaMAX™ containing 10 nM calcein AM, in a ﬁnal
concentration of 100 μl/well. Cells were incubated with calcein AM
at 37 °C for 30 min, protected from light, and cells in suspension
were intermittently agitated.000 beads per sample (gates A) andmedium-treated cells. Live cells (gates B) are calcein-
g (histograms). In the lower panels PBMC were added as effector cells (gate E) that can be
age cells speciﬁcally lysed by the compound under study. ‘Number of calcein positive live
riplicate measurement of calcein positive target cells inwells with complement or effector
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PBMC were isolated from buffy coats (Sanquin) by density gradient
centrifugation and cryopreserved to secure equal PBMC quality for all
assays. PBMC from two donors were used (see Tables 2 and 3). The
NK cell ratio for each PBMC batch was determined by ﬂow cytometry
using mouse anti-human CD56 APC (BioLegend) and mouse anti-
human CD16 PE/Cy7 (Beckman Coulter). Thawed PBMC were cultured
overnight in complete medium for suspension cells at a density of
1 × 106 cells/ml. For ADCC assays on Ramos cells with rituximab,
500 IU/ml recombinant IL-2 (Aldesleukin) was added during the over-
night incubation. The optimal concentration of effector cells was deter-
mined at 12.5 × 106 PBMC/ml in complete medium for suspension and
adherent cells.Fig. 2. CDC and ADCC of suspension cells. (A) Representative examples of CDC and ADCC as me
Rituximab was added at a concentration of 1000 ng/ml. (B) CDC of suspension cells with ritu
82 ng/ml) and Raji cells (right; EC50 24 ng/ml). (C) ADCC of suspension cells with rituximab
1.02 ng/ml). (D) Comparison of the LDH release assay, the calcein release assay and the
experiment, using the same batch of effector cells. Background signals are 70.9%, 54.3% and 1
assay, respectively. (E) Antibody dose response curves for the three cytotoxicity assays. Ritu
maximum cell death; EC50 3.7 ng/ml), LDH release assay (open circles, 58% maximum cell de
71% maximum cell death; EC50 2.3 ng/ml). In A-C PBMC donor 4 was used, in D and E PBMC d2.4. Conventional calcein release assay
Ramos target cells were labeled with 2 μM calcein AM as described
above. For ADCC, target cells were incubated with antibody (see
below) and PBMC for 4 h, with 2% Triton (Sigma) added for the ﬁnal
5 min to ensure maximum calcein release. After centrifugation, cell free
supernatantwas transferred to a Cellcarrier plate (Perkin Elmer) tomea-
sure relative ﬂuorescence units (RFU) using a HTSmultilabel reader (En-
vision; Perkin Elmer). The percentage of speciﬁc lysis was calculated as
follows: ((RFU value in respective treatment − RFU value in control
(spontaneous release) / (RFU value Triton (maximum release)− RFU
value in control (spontaneous release)) × 100. The background of the
assay was calculated as follows: (RFU value in control (spontaneous re-
lease) / RFU value Triton (maximum release)) × 100.asured by the modiﬁed calcein AM retention assay. Ramos cells were used as target cells.
ximab (open triangles) or control antibody (closed squares) on Ramos cells (left; EC50
or control antibody on Ramos cells (left; EC50 of 1.2 ng/ml) or Raji cells (right; EC50 of
calcein AM retention assay to measure ADCC with Ramos cells as target cells in one
5% for the LDH release assay, the calcein release assay and the modiﬁed calcein retention
ximab induced ADCC of Ramos cells with the calcein release assay (open triangles, 49%
ath; EC50 3.0 ng/ml) and the modiﬁed calcein retention assay (green, closed diamonds,
onor 14 was used.
Fig. 2 (continued).
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Unlabeled Ramos cells were incubated with antibody (see below)
and PBMC for 4 h at 37 °C in 5% CO2, with Triton added during the last5 min for maximum LDH release. Cells were incubated with a reaction
mixture (Cytotoxicity Detection Kit Plus (Roche)) for 20 min at room
temperature. The reaction was stopped and optical density was mea-
sured at a wavelength of 492 nm on an Envision. The percentage of
20 M.A. Gillissen et al. / Journal of Immunological Methods 434 (2016) 16–23speciﬁc lysis was calculated as described above. PBMC and target cell
only conditions were used to measure spontaneous release; for maxi-
mum release triton was added. The background of the assay was calcu-
lated as described above.
2.6. Flow cytometry based calcein retention assay
Calcein AM labeled suspension cells werewashed twice, adjusted to a
cell concentration of 0.5 × 106/ml medium and put in U bottom 96-well
microtiter plates (Becton Dickinson Falcon™) at a concentration of
1.25 × 104 cells per well (25 μl). Calcein AM labeled adherent cells were
on the day of the assay also with 1.25 × 104 cells per well. Antibodies
were added at 1:4 dilution (25 μl) and left for opsonization at room tem-
perature for 15 min. The following antibodies were used: trastuzumab
(anti HER2/neu, Herceptin®; Roche), rituximab (anti CD20, Mabthera®;
Roche), palivizumab (anti RSV-F, Synagis®; Medimmune), and the in-
housemanufacturedmonoclonal antibodies AM22 (anti Respiratory Syn-
cytial Virus-F) and AT10-002 (anti inﬂuenza virus, hemagglutinin H3)
(McLellan et al., 2013; Wagner et al., 2014). For CDC 50 μl of 20% rabbit
serum complement (Sigma) was added. For ADCC 50 μl PBMC were
added at an effector-to-target (E:T) cell ratio of 50:1. Cellswere incubated
at 37 °C in 5% CO2 and left for 1 h for CDC and 4h for ADCC. Adherent cells
were detached with trypsin- EDTA (50 μl/well) and transferred to a
round bottom 96-well microtiter plate. Samples were measured using a
FACSCanto II (BectonDickinson) or FACS LSR FortessaX-20 (BectonDick-
inson). To assure equal assay volumes, 10,000 Accudrop Fluorescent
Beads (Becton Dickinson) were added to every sample and 5000 beads
acquired per sample. Data analysis was performed using FlowJo software
(TreeStar) and the number of live cells was determined by calcein high
green ﬂuorescent signal. The percentage of speciﬁc lysis was calculated
as follows: 100− ((calcein positive cells in respective treatment/calcein
positive cells in untreated control) × 100). Experiments were performed
in duplo in at least two separate experiments. The background (sponta-
neously died target cell) of the assay was calculated with the live cell
number in the medium control sample and the actual number of target
cells that was started with.
2.7. EC50
GraphPad PrismVersion 6.0f forMacOSXwas used to analyze dose-
response data. XY data tables were made with antibody concentration
(X) and cell lysis % (Y). Then, X values were transformed logarithmical
(X=LogX) and a nonlinear regression (curve ﬁt) analysis and a sigmoi-
dal dose-response curvewas created to calculate the halfmaximal effec-
tive concentration (EC50) and the 95% conﬁdence interval (95% CI).
3. Results
3.1. Calcein AM labeling and quantiﬁcation of live cells
To reliably quantify the capacity of compounds to induce death of
target cells, we set up an assay that is based on the green-ﬂuorescent la-
beling of living cells with calcein. Target cells were labeled with calcein
AM that is contained in the cytoplasm of live cells and emits a green
ﬂuorescent signal (Emissionmax 512 nm) when excited with a 488 nm
laser. To be able to measure the same volume for any given sample weTable 1
EC50 values of rituximab-induced CDC.
Target cell Antibody Method
Ramos Rituximab ATP luminescence
Ramos Rituximab Modiﬁed calcein retention assay
Raji Rituximab ATP luminescence
Raji Rituximab Cr release
Raji Rituximab Modiﬁed calcein retention assay
95% CI: 95% conﬁdence interval of the calculated EC50.added 10,000 Accudrop ﬂuorescent beads (Becton Dickinson) per sam-
ple and acquired a ﬁxed number of 5000 bead events for each sample. In
the forward scatter (FSC) versus side scatter (SSC) plot these FACS
beads appeared as a narrow band (Fig. 1A, gates A) that can be easily
separated from the cells in the sample (Fig. 1A, gates B). Live cells
were gated out as calcein-positive green ﬂuorescent bright cells; these
are DAPI negative (Fig. 1A, gates C). Dead cells are either calcein-
negative cells; these are DAPI positive (Fig. 1A, gates D) or have dissem-
inated and are therefore not visible anymore. Effector cells (PBMCs) that
were added to the sample can be gated out as calcein-negative cells
(Fig. 1A, gate E). To calculate the percentage of live cells per sample
we used the equation depicted in Fig. 1B. The actual number of calcein
positive cells was calculated for each cell sample using FlowJo software.
To compensate for random cell death induced by cell handling, incuba-
tion, complement or PBMCs we normalized cell death to the number of
dead cells in the control sample (cells handled similarly to the samples
of interest, including incubation with complement or PBMCs, but treat-
ed withmedium not containing antibodies; ‘number of calcein-positive
cells in control’). This medium control sample was set as 100% survival.
3.2. Complement dependent cytotoxicity assay on suspension cells
We then validated themodiﬁed FACS calcein AM retention assay for
quantifying cell viability by therapeutic antibodies. Rituximab is a CD20-
speciﬁc monoclonal antibody that induces CDC and ADCC of B cells, in-
cluding the B cell lines Ramos and Raji (Bornstein et al., 2009). Ramos
and Raji target cells were labeled with calcein AM and incubated with
complement containing rabbit serum to a ﬁnal concentration of 10%
and rituximab or control antibody. One representative example is
depicted in Fig. 2A (left panels). Dose-response analysis of rituximab
concentrations ranging from0.5 to 3300 ng/ml yielded sigmoidal curves
(Fig. 2B) and EC50 values of 82 and 24 ng/ml for Ramos and Raji,
respectively, with narrow 95% EC50 conﬁdence intervals (Table 1).
Complement-containing rabbit serum alone was very well tolerated
by the cells resulting less than 5% background cell death. Additional vi-
sualization of this process was performed with a high content imager
(Operetta, PerkinElmer; 10× objective). Loss of green ﬂuorescence is
clearly visible for Rituximab on Ramos cells, whereas no loss of ﬂuores-
cence is observed for the negative control antibody Palivizumab (Sup-
plementary Fig. 1).
3.3. Antibody dependent cellular cytotoxicity on suspension cells
To measure ADCC, calcein labeled target cells were incubated with
human PBMC from healthy donors. A range of effector-to-target (E:T)
cell ratios were tested in duplicate. For both batches of PBMC that
were used in these assays, the optimal E:T ratio was 50:1. The percent-
age of CD56+NK cells per PBMC sample used in our assays was around
10%, resulting in a NK effector: target cell ratio of 5:1. Calcein-labeled
Ramos and Raji B lymphocyteswere incubatedwith PBMC and different
concentrations of rituximab. In Fig. 2A (right panels) a representative
example is depicted. Dose-response tests again yielded sigmoidal
curves with limited variation between duplicates as can be observed
by the narrow 95% conﬁdence interval and EC50 values of 1.2 and
1.02 ng/ml for Ramos and Raji cells, respectively (Fig. 2C and Table 2).EC50 (ng/ml) (95% CI) Reference
110 Bornstein ea (Bornstein et al., 2009)
82 (41.55–105.60) This paper
180 Bornstein ea (Bornstein et al., 2009)
50 Winiarska ea (Winiarska et al., 2008)
24 (18.41–33.21) This paper
Table 3
Direct comparison between assays.
Target cell Antibody Method EC50 in
ng/ml
95% CI
Ramos Rituximab Calcein release 3.7 0.84–16.43
Ramos Rituximab LDH release 3.0 1.45–6.38
Ramos Rituximab Modiﬁed calcein
retention assay
2.3 1.95–3.20
Frozen PBMCs from donor 14 were used as effector cells.
95% CI: 95% conﬁdence interval of the calculated EC50.
Table 2
EC50 values of rituximab and trastuzumab-induced ADCC.
Target cell Antibody Method EC50 in ng/ml (95% CI) Reference
Ramos Rituximab LDH release 16 Breton ea (Breton, 2014)
Ramos Rituximab LDH release 10 Heider ea (Heider et al., 2011)
Ramos Rituximab Not speciﬁed 9.6 Bornstein ea (Bornstein et al., 2009)
Ramos Rituximab Reporter bioassay 19 Cheng ea (Cheng et al., 2014)
Ramos Rituximab Modiﬁed calcein retention assay 1.1 (0.89–1.28) This paper
Raji Rituximab Not speciﬁed 2.8 Bornstein ea (Bornstein et al., 2009)
Raji Rituximab LDH release 12 Breton ea (Breton, 2014)
Raji Rituximab Reporter bioassay 19 Cheng ea (Cheng et al., 2014)
Raji Rituximab Cr release 16.2 Le Garff ea (Le Garff-Tavernier et al., 2010)
Raji Rituximab Modiﬁed calcein retention assay 1.02 (0.70–1.54) This paper
SK-BR-3 Trastuzumab Reporter bioassay 10 Murray ea (Murray, 2014)
SK-BR-3 Trastuzumab Reporter bioassay 11 Cheng ea (Cheng et al., 2014)
SK-BR-3 Trastuzumab Calcein retention 16 Prang ea (Prang et al., 2005)
SK-BR-3 Trastuzumab Modiﬁed calcein retention assay 0.17 (0.13–0.22) This paper
Frozen PBMC from donor 4 were used as effector cells.
95% CI: 95% conﬁdence interval of the calculated EC50.
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calcein release assay and the LDH release assay side by side in one ex-
periment (Table 3). Spontaneous LDH release was high, resulting in
a ~ 70% background signal in the LDH release assay. The calcein release
assay had ~54% background signal whereas the calcein retention assay
had a background signal of only 15%. The remaining window of 85% of
the signal, which can be used for calculating speciﬁc lysis, makes the
FACS calcein AM retention assay the most sensitive assay (Fig. 2D). In
Fig. 2E the dose response curves of the threemethods to quantify Ritux-
imab induced ADCC of Ramos cells are shown. The FACS calcein AM re-
tention assay yielded the lowest EC50 value, as well as the narrowest
95% EC50 conﬁdence interval (CI) (2.3 ng/ml (CI 1.95–3.2) vs 3.7 (CI
0.84–16.43) and 3.0 (CI 1.45–6.38) ng/ml for the calcein release assay
and the LDH release assay, respectively; see also Table 3). Themaximum
amount of cells killed varied between assays and the ability of Rituxi-
mab to induce ADCC was underestimated by 30% when measured
with the LDH assay and by ~60% when measured with the calcein re-
lease assay.
3.4. Antibody dependent cellular cytotoxicity on adherent cells
We then applied the modiﬁed FACS calcein AM retention assay to
adherent cells using the breast cancer cell line SK-BR-3. In conventional
cytotoxicity assays adherent cells are detached prior to the assay. To
overcome detachment-related effects on cell viability, we plated adher-
ent cells 3 days prior to the cytotoxicity assay on a Poly-D-Lysin coated
plate. At the day of the cytotoxicity assay adherent cells were labeled
with calcein AM, without detaching them. This approach resulted in
the use of viable, calcein labeled cells in the assay (Fig. 3A, left panels).
Incubation of calcein labeled breast cancer SK-BR-3 cells with PBMC
and trastuzumab resulted in death of target cells with a sigmoidal
dose-response curve (Fig. 3B). The EC50 for trastuzumab on SK-BR-3
cells was 0.17 ng/ml (Table 2).
4. Discussion
Established methods to determine the cytotoxicity of any given
compound in vitro are negatively affected by non-speciﬁc signals
caused by auto-ﬂuorescence of target and effector cells and random
cell death that leads to underestimations of the activity of the com-
pound under study. To overcome this, we developed a novel cytotoxic-
ity assay in whichwe combined and optimized established cell viability
assays. This resulted in an exceptionally sensitive method that allows
for single cell analysis by high throughput FACS. As shown in Table 1
(CDC) and Table 2 (ADCC), the EC50 values obtained with this modiﬁed
FACS calcein AM retention assay are considerably lower compared to
published data (Bornstein et al., 2009; Cheng et al., 2014; Prang et al.,2005; Winiarska et al., 2008; Heider et al., 2011; Breton, 2014; Le
Garff-Tavernier et al., 2010;Murray, 2014). For example, using the chro-
mium 51 (51Cr) release assay(Le Garff-Tavernier et al., 2010) and the
reporter-based ADCC bioluminescence assay (Promega)(Cheng et al.,
2014; Parekh et al., 2014) to measure ADCC of Raji cells by rituximab
yielded an EC50 of around 17 ng/mg (19 vs 16.2). The LDH release
assay generated a somewhat lower EC50 of 12 ng/ml (Breton, 2014. In
our hands, the calcein release assay and the LDH release assay yielded
an EC50 of 3.7 ng/ml and 3.0 ng/ml, respectively, while depending on
the batch of effector cells used the modiﬁed FACS calcein AM retention
assay produced an EC50 of 1.2 to 2.3 ng/ml (Table 3). The high sensitiv-
ity of our assay is the result of a much higher accuracy of compound-
speciﬁc cell viability analysis as the assay focuses on live cells instead
of dead cells. Spontaneous release of enzymes or radioactive isotopes
does not interfere with the analysis and background signals are thereby
compensated for.
The modiﬁed calcein retention assay has other advantages. With its
focus on live cells, it allows for less strict timing of analysis as it takes
into account all mechanism of cell death (e.g. apoptosis, necroptosis,
oncosis). It should be noted that very early apoptotic cells are not de-
tected with any of these methods, as early in the apoptotic pathway
the cell membrane is intact and Cr51, calcein and LDH are contained in
the cell. This can be overcome by co-staining with an early apoptotic
marker like Annexin V, which stains the ﬂipped phosphatidylserine.
Furthermore, for laboratories that have a ﬂow cytometer available the
assay is relatively cheap compared to commercially available kits, the
read-out is simple, and the assay is safe, as it does not employ toxic or
radioactive materials.
EC50 values obtained with our assay were highly reproducible with
less than 0.1 ng/ml variation, but only when the same batch of PBMCs
was used. The effector cell function of PBMC is to a large extent deter-
mined by the percentage of NK cells present and their cytotoxic capac-
ity, which is amongst others dependent on the CD16 FcγRIIIa receptor
polymorphism. CD16 Fc receptors with a valine at position 158 have a
Fig. 3. ADCC of adherent cells. (A) Representative example of ADCC of the adherent breast cancer cell line SK-BR-3 by trastuzumab. Viable adherent cells can be labeled with calcein (left
panels). Addition of effector cells and trastuzumab (1000 ng/ml) resulted in ADCC (right panels). (B) Dose-response curve of trastuzumab (open triangles) or control antibody (closed
squares). In all experiments PBMC from donor 4 were used.
22 M.A. Gillissen et al. / Journal of Immunological Methods 434 (2016) 16–23higher afﬁnity for IgG compared to CD16 Fc receptors with a phenylala-
nine at that position (Koene et al., 1997; Hatjiharissi et al., 2007). This
may result in more efﬁcient effector function of NK cells, however, it is
not the only determinant of effector function. Both batches of PBMC
that we used had the same FcγRIIIa receptor polymorphism but were
isolated at different time-points and showed different effector function.
It has been demonstrated that blood processing can impact on NK cell
activation and function, and this may add to the variability of NK cell
function in ADCC assays (Naranbhai et al., 2011). Thus, the inter-
donor variation for effector cells is large, and PBMC should be tested
for their ADCC potency before new compounds are investigated. With
the use of CD16 expressingNK cell linesmore stable and comparable re-
sults may be obtained (Chung et al., 2014).
Taken together, we have developed an extremely sensitive, repro-
ducible, high throughput ﬂow cytometer based method to determine
cellular cytotoxicity, which can be applied to test the cytotoxicity of
compounds in vitro.
Supplementary data to this article can be found online at http://dx.
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